TAT-11: The Use of Albumin Binders as a Strategy to Optimize Tumor Delivery

Ottawa, ON, Canada (UroToday.com) This study aims to improve the therapeutic efficacy of Lu177-PMSA617 by adding an albumin binder to the conjugated ligand. To this end, a new conjugate, Lu177-HTK01169 was developed containing the albumin binder. A comparison was carried out in mice with PSMA-expressing LNCaP tumor xenografts the Lu177-HTK01169 tumor uptake was more than 8 times higher than PSMA617, though because of renal excretion the kidney uptake was higher too.

Overall survival was also much better: >120 days for Lu177-HTK01169 compared to 58 days for PSMA617 or 14 days for the saline control sample. In the future, they plan to improve kidney uptake by optimization of the albumin binder.


Presented by: Kuo-Shyan Lin, Ph.D., Senior Scientist, Department of Molecular Oncology, and Associate Professor, Radiology, the University of British Columbia, Department of Radiology, Vancouver, British Columbia, Canada

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada